Send to

Choose Destination
J Neurotrauma. 2006 Aug;23(8):1201-10.

Serum biochemical markers for post-concussion syndrome in patients with mild traumatic brain injury.

Author information

Department of Emergency Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.


Mild traumatic brain injury (MTBI) is a major public health problem in the United States. A significant subset of MTBI patients develop persistent and distressing neurological, cognitive, and behavioral symptoms, known as the post-concussion syndrome (PCS). To date, multiple studies have assessed the relationship between brain-related proteins found in the serum at the time of injury, and the development of PCS. We conducted a systematic review of prospective cohort studies that assessed the ability of serum biochemical markers to predict PCS after MTBI. A total of 11 studies assessing three different potential biochemical markers of PCS--S100 proteins, neuron-specific enolase (NSE), and cleaved Tau protein (CTP)--met selection criteria. Of these markers, S100 appeared to be the best researched. We conclude that no biomarker has consistently demonstrated the ability to predict PCS after MTBI. A combination of clinical factors in conjunction with biochemical markers may be necessary to develop a comprehensive decision rule that more accurately predicts PCS after MTBI.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Mary Ann Liebert, Inc.
Loading ...
Support Center